<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226456</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-NAC</org_study_id>
    <nct_id>NCT04226456</nct_id>
  </id_info>
  <brief_title>Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity</brief_title>
  <official_title>Clinical Trial: Intratympanic Injection of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, randomized, controlled, open label phase IV superiority trial.&#xD;
&#xD;
      After signing the informed consent form and upon the confirmation of the patient eligibility,&#xD;
      patients will be randomized 1:1 to the experimental arm (NAC + Cisplatin) or the standard arm&#xD;
      (Cisplatin).&#xD;
&#xD;
      The primary objective of this trial is to evaluate the protecting effect of Lysomucil® 10%&#xD;
      against Cisplatin-induced ototoxicity. In this case, we will evaluate its effect through the&#xD;
      transtympanic administration in both ears.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apparition of ototoxicity</measure>
    <time_frame>6 month after last injection</time_frame>
    <description>the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:&#xD;
A Threshold shift of 15 - 25 decibel (dB) averaged at 2 contiguous test frequencies in at least one ear&#xD;
and/or the apparition of a tinnitus (not previously present).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the apparition of ototoxicity defined by the inclusion of high frequency audiometry (Tune Grading System)</measure>
    <time_frame>6 month after last injection</time_frame>
    <description>the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:&#xD;
A Threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear&#xD;
and/or the apparition of a tinnitus (not previously present).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hearing quality of life: Evaluation of the Impact of Hearing Loss in Adults ERSA</measure>
    <time_frame>6 month after last injection</time_frame>
    <description>Evaluation of the Impact of Hearing Loss in Adults (ERSA) For each question, the score of 0 means maximal difficulties, the sore of 10 means ideal situation Formulation is uniform, with no inversions: 0 always corresponds to maximal difficulty and 10 to an ideal situation, so that the lower the score the greater the impact of hearing loss on quality of life. Maximum score is 200 for respondents in work and 150 for those not in work or in retirement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hearing quality of life: Tinnitus Handicap Index (THI)</measure>
    <time_frame>6 month after last injection</time_frame>
    <description>Tinnitus Handicap Index (THI) score Range : 0 to 100. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ototoxic Hearing Loss</condition>
  <condition>Ototoxic Hearing Loss, Bilateral</condition>
  <condition>Ototoxicity</condition>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)&#xD;
Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm (Arm B):&#xD;
0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.&#xD;
Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)&#xD;
Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18-year-old&#xD;
&#xD;
          -  Patients suffering from a neoplastic disease for which treatment protocol includes&#xD;
             Cisplatin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential pregnant or with intention to become pregnant within&#xD;
             the trial duration&#xD;
&#xD;
          -  Pathological findings on otoscopy that do not allow safe intratympanic drug delivery&#xD;
             and reliable distortion product otoacoustic emissions (DPOAEs) testing.&#xD;
&#xD;
          -  Conductive hearing loss &gt; 10 decibel hearing level (dBHL)&#xD;
&#xD;
          -  Meniere disease&#xD;
&#xD;
          -  Medical history of sudden hearing loss&#xD;
&#xD;
          -  Sensorineural Hearing loss (SNHL) with mean ≥ 40dbHL Pure Tonal Audiometry (PTA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gaëtan CAVELIER, MD</last_name>
    <phone>003225354267</phone>
    <email>gaetan_cavelier@stpierre-bre.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mihaela Horoi, MD</last_name>
    <phone>003225354267</phone>
    <email>mihaela_horoi@stpierre-bru.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaëtan Cavelier, MD</last_name>
      <phone>0476613044</phone>
      <email>gaetan.cavelier@stpierre-bru.be</email>
    </contact>
    <contact_backup>
      <last_name>Mihaela Horoi, MD, PhD</last_name>
      <email>mihaela.horoi@stpierre-bru.be</email>
    </contact_backup>
    <investigator>
      <last_name>Gaetan Cavelier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihaela Horoi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Boegner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Tinnitus</mesh_term>
    <mesh_term>Ototoxicity</mesh_term>
    <mesh_term>Hearing Loss, Bilateral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

